touchONCOLOGY joins Dr Domenica Lorusso (Rome, Italy), to discuss the improvements in progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant in combination with nab-paclitaxel. (NCT03776812)
Question
Please summarise the randomized, open-label, phase II study presented at ESMO 2021 exploring progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel.
- Rationale and aims of the study: 00:30-04:05
- Primary endpoints and results: 04:05-06:17
- Conclusions and impact on future treatment: 06:17-07:29
Disclosures: Domenica Lorusso has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ESMO 2021 Annual Meeting.
